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Introduction
Viability assessment by delayed-enhanced (DE) MR in
patients with coronary artery disease (CAD) can pre-
dict improvement of ejection fraction (EF) after revas-
cularization. However it is implication on survival is
incompletely understood. Several studies suggested
that large amounts of of DE, ie non-viable myocar-
dium, increase risk of death. However these studies did
not take into account the presence of CAD and and
the potential protective effect of revascularization ther-
apy on outcome. Also they conflict with earlier work
employing nuclear imaging or Dobutamine Echocar-
diography who reported that large amounts of viable
myocardium predict worse outcome if such myocar-
dium is not revascularized.
Purpose
The aim of the present work was to evaluate how viabi-
lity by DE-MR predicts the survival in patient with low
EF when revascularization of CAD is taken into account.
Methods
We evaluated survival of patients who satisfied to Felk-
ers definition of ischemic cardiomyopathy with EF<35%
and who underwent DE-MR for assessment of myocar-
dial viability and who had not been revascularized at the
time of MR. The number of dysfunctional segments and
the transmurality of DE was scored visually in 17 seg-
ments per patient. Kaplan-Meyer and Cox survival ana-
lysis was performed evaluating the predictive value of
E F ,v o l u m e s ,t r e a t m e n t ,a n dn u m b e ro fd y s f u n c t i o n a l
segments with necrosis
Results
131 patients with a mean EF of 23±7% were followed.
7 pts. had one vessel disease (all proximal LAD disases),
35 2-vessel disease and 89 3-vessel disease. 75 patients
underwent revascularization by CABG, and 23 by
PTCA, while 34 remained under medical treatment. Fol-
low-up was 100% complete at a median of 3.5 years.
43 pts died (all but 7 from cardiac cause) and 4 under-
went heart transplantation. Four-year survival was sig-
nificantly better in revascularized patients (75%) than in
medically treated patients (46%, p<0.02 by log-rank
test). Cox survival analysisd e m o n s t r a t e dt h a to n l y
revascularization therapy was an independent predictor
of survival. Presence of viability by DE-MR was not
independently associated with survival either in revascu-
larized or medically treated patients. Revascularization
therapy significantly improved survival even in the
absence of myocardial viability.
Conclusions
In patients with ischemic cardiomyopathy, revasculariza-
tion therapy is most important parameter associated
with survival. Presence or absence of myocardial viability
did not provide additional information on survival of
patients. We thus conclude that all patients with
ischemic cardiomyopathy will benefit from revasculari-
zation therapy, irrespectively of presence or absence of
myocardial viability by DE-MR.
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